

PARP INHIBITORS: Their Role in the Treatment of Ovarian Cancer

An educational community hospital series for community oncologists

Invite an expert to your community-based institution for a clinician-driven speaker program. The speaker series will interweave a didactic presentation with ARS for a unique interactive experience.

PROGRAM OVERVIEW

Given the recent approval of several PARP inhibitors, as well as the associated volume of emerging data, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy, and prevent and manage adverse events (AEs).

This program will help provide expert guidance to your institution regarding the use of existing PARP inhibitors and companion diagnostics safely and effectively, as well as to plan for optimal integration of new agents and indications into practice when they become available.

This CME-certified interactive speaker series will be available through March 2018.

PROGRAM FACULTY

COURSE DIRECTOR

Robert L. Coleman, MD, FACOG, FACS
The University of Texas
MD Anderson Cancer Center
Houston, Texas

CONTENT VALIDATOR

Ursula A. Matulonis, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

FACULTY

Michael J. Birrer, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Thomas Herzog, MD
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Douglas A. Levine, MD
NYU Langone Medical Center
New York, New York

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology
University of Arizona College of Medicine
Phoenix, Arizona

R. Wendel Naumann, MD, FACOG, FACS
Carolinas Medical Center
Charlotte, North Carolina

David M. O'Malley, MD
The Ohio State University
Columbus, Ohio

Matthew A. Powell, MD
Washington University School of Medicine
St. Louis, Missouri

Shannon N. Westin, MD, MPH, FACOG
The University of Texas
MD Anderson Cancer Center
Houston, Texas

CONTINUING EDUCATION

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of *1.0 AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend

TARGET AUDIENCE

Gynecologic oncologists, medical oncologists, and other allied healthcare providers caring for patients with ovarian cancer.

LEARNING OBJECTIVES

- Evaluate the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition
- Assess the role of PARP in DNA repair, as well as the rationale for targeting PARP in ovarian cancer patients with BRCA-mutated disease
- Appraise data of emerging PARP inhibitors undergoing clinical trial examination for proper use of current available PARP inhibitors
- Identify strategies to prevent and manage side effects of PARP inhibition to improve patient outcomes and adherence

FACULTY AND PLANNING COMMITTEE DISCLOSURES

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments

not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

All disclosed conflicts of interest have been resolved by independent content review.

SUPPORT STATEMENT

This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Inc., and Tesaro, Inc.

REQUEST AN ACTIVITY

PLEASE COMPLETE THE FORM AND EMAIL OR FAX AS DIRECTED

PARP INHIBITORS: Their Role in the Treatment of Ovarian Cancer

This CME-certified series will be available through March 2018. To host this activity, please download this form and submit it to cme@bioascend.com or fax to 800-210-8231.

CONTACT

NAME

INSTITUTION

ADDRESS

CITY

STATE

ZIP

PHONE

FAX

EMAIL ADDRESS

PROGRAM SETTING

GRAND ROUNDS

TUMOR BOARD

OTHER

PLEASE PROVIDE THE ESTIMATED AUDIENCE BREAKDOWN NUMBERS

Gyn Onc MDs

Other MDs

Other

Med Onc MDs

Pharmacists

Surg Onc MDs

Nurses

AVAILABLE PROGRAM DATES

AVAILABLE PROGRAM TIME

PREFERRED SPEAKER(S)

1st Choice

2nd Choice

3rd Choice

CME CREDIT (This activity is accredited by the University of Nebraska Medical Center)

MY INSTITUTION WILL PROVIDE CME CREDIT FOR THIS ACTIVITY.

May we obtain a copy of the completed sign-in sheet upon conclusion of the activity?

YES NO

AV EQUIPMENT (please check all items you can provide)

PROJECTOR SCREEN OR TV PROJECTOR SLIDE ADVANCER

May we provide Audience Response Technology (ARS)

YES NO

A Bio Ascend representative will be onsite to administer this technology. Please note, we may be required to use our laptops to run this software

OUTSIDE ATTENDEES

Can this activity be open to outside HCP attendees?

YES NO

INDUSTRY ATTENDANCE

Can industry attend this activity?

YES NO

If yes, are there specific on-site requirements we should communicate?

CATERING

Will you need us to provide catering for this activity?

YES NO

MEETING LOCATION ADDRESS (if different from above)

ADDRESS

CITY STATE ZIP

ROOM NAME (EG, 1st floor conference room) FAX

ON-SITE CONTACT

EMAIL ADDRESS